Sarah Madras's questions to Acumen Pharmaceuticals Inc (ABOS) leadership • Q1 2025
Question
Sarah Madras from Cantor Fitzgerald inquired about the statistical powering for the ALTITUDE study, whether an interim analysis is planned, and how recent biomarker advancements inform Acumen's clinical strategy and top-line expectations.
Answer
Dr. Eric Siemers, Chief Medical Officer, confirmed there is no interim analysis and stated the 542-participant study is appropriately powered for Phase II. He and Dr. James Doherty, President and Chief Development Officer, explained that while the primary endpoint is the clinical iADRS scale, their Phase I study showed promising early biomarker changes, which provide crucial context and evidence of central pharmacology.